AR038091A1 - Composiciones farmaceuticas que comprenden un inhibidor multifuncional de la fosfodiesterasa y un inhibidor de la captacion adenosina - Google Patents

Composiciones farmaceuticas que comprenden un inhibidor multifuncional de la fosfodiesterasa y un inhibidor de la captacion adenosina

Info

Publication number
AR038091A1
AR038091A1 ARP020105132A ARP020105132A AR038091A1 AR 038091 A1 AR038091 A1 AR 038091A1 AR P020105132 A ARP020105132 A AR P020105132A AR P020105132 A ARP020105132 A AR P020105132A AR 038091 A1 AR038091 A1 AR 038091A1
Authority
AR
Argentina
Prior art keywords
inhibitor
pharmaceutical compositions
multifunctional
adenosine
phosphodesterase
Prior art date
Application number
ARP020105132A
Other languages
English (en)
Original Assignee
Otsuka Maryland Res Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Maryland Res Inst Inc filed Critical Otsuka Maryland Res Inst Inc
Publication of AR038091A1 publication Critical patent/AR038091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se relaciona con composiciones farmacéuticas que comprenden por lo menos un inhibidor multifuncional de la fosfodiesterasa (MPDEI) y por lo menos un inhibidor de la captación de adenosina. También se relaciona con composiciones que comprenden cilostazol y dipiradamol y con sus usos, para el tratamiento de variedad de síntomas y enfermedades, entre las que se incluye la isquemia de miembros y la claudicación intermitente (Cl) asociadas con la enfermedad oclusiva arterial periférica (EOAP), para la prevención y tratamiento de la apoplejía y para la prevención de la trombosis y restenosis coronarias.
ARP020105132A 2001-12-27 2002-12-27 Composiciones farmaceuticas que comprenden un inhibidor multifuncional de la fosfodiesterasa y un inhibidor de la captacion adenosina AR038091A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34236701P 2001-12-27 2001-12-27
US41254602P 2002-09-23 2002-09-23

Publications (1)

Publication Number Publication Date
AR038091A1 true AR038091A1 (es) 2004-12-29

Family

ID=26992976

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105132A AR038091A1 (es) 2001-12-27 2002-12-27 Composiciones farmaceuticas que comprenden un inhibidor multifuncional de la fosfodiesterasa y un inhibidor de la captacion adenosina

Country Status (15)

Country Link
US (3) US20050165030A1 (es)
EP (1) EP1461039B1 (es)
JP (1) JP2005517680A (es)
KR (1) KR20040083072A (es)
CN (1) CN1607952A (es)
AR (1) AR038091A1 (es)
AU (1) AU2002360798A1 (es)
BR (1) BR0215392A (es)
CA (1) CA2471846A1 (es)
DK (1) DK1461039T3 (es)
ES (1) ES2525418T3 (es)
MX (1) MXPA04006275A (es)
PT (1) PT1461039E (es)
TW (1) TW200301135A (es)
WO (1) WO2003057222A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2008545808A (ja) * 2005-05-23 2008-12-18 エラン・ファルマ・インターナショナル・リミテッド 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
US7811549B2 (en) 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
WO2008076841A1 (en) * 2006-12-14 2008-06-26 Biokey, Inc. Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
WO2008143361A1 (en) * 2007-05-22 2008-11-27 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
US20090185973A1 (en) * 2008-01-22 2009-07-23 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
US20110092456A1 (en) * 2009-10-19 2011-04-21 Yochai Birnbaum Methods of increasing cAMP levels and uses thereof
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102131612B1 (ko) 2011-09-02 2020-07-08 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP7036670B2 (ja) * 2018-05-31 2022-03-15 アークレイ株式会社 血液中の稀少細胞検査、該検査ための血液処理方法及び採血管
JP7332489B2 (ja) * 2019-01-28 2023-08-23 サントリーホールディングス株式会社 ホスホジエステラーゼ３阻害用組成物及び血小板凝集抑制用組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
CN1658903A (zh) * 2001-01-26 2005-08-24 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与血液调节剂的组合

Also Published As

Publication number Publication date
CN1607952A (zh) 2005-04-20
TW200301135A (en) 2003-07-01
CA2471846A1 (en) 2003-07-17
KR20040083072A (ko) 2004-09-30
DK1461039T3 (en) 2015-01-12
ES2525418T3 (es) 2014-12-22
EP1461039A1 (en) 2004-09-29
WO2003057222A1 (en) 2003-07-17
EP1461039B1 (en) 2014-10-22
US20080200484A1 (en) 2008-08-21
PT1461039E (pt) 2014-12-12
US20100184784A1 (en) 2010-07-22
AU2002360798A1 (en) 2003-07-24
JP2005517680A (ja) 2005-06-16
US20050165030A1 (en) 2005-07-28
BR0215392A (pt) 2004-12-07
MXPA04006275A (es) 2004-10-04

Similar Documents

Publication Publication Date Title
AR038091A1 (es) Composiciones farmaceuticas que comprenden un inhibidor multifuncional de la fosfodiesterasa y un inhibidor de la captacion adenosina
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
CR7235A (es) Inhibidores beta- amino tetrahidroimidazol (1,2-a) pirazinas y tetrahidrotrioazolo (4,3-a) pirazinas como depetidil peptidasa para el tratamiento o prevencion de la diabetes
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
AR052034A1 (es) Sal potasica de un inhibidor de la integrasa de vih
BRPI0411916A (pt) imidazoquinolinas substituìdas por sulfonamida
NO20061627L (no) Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
ECSP045178A (es) Compuestos de aril úrea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
BR0206501A (pt) Inibidores de cruzipaìna e outras cisteìna proteases
PA8552501A1 (es) 1-alquil o 1-cicloalquil-triazolo[4,3-a]quinazolin-5-onas como inhibidoras de fosfodiesterasa
HRP20040758B1 (hr) Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
HN2004000146A (es) Dihidroquinazolinas sustituidas
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
UY26156A1 (es) Aril y heteroaril pirimidonas policíclicas sustituidas útiles para la inhibición selectiva de la cascada de coagulación
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
ATE380188T1 (de) Substituierte chinolone
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
BRPI0408299A (pt) inibidores de catepsina s
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer

Legal Events

Date Code Title Description
FB Suspension of granting procedure